{"filings":[{"id":732036,"accession_number":"0001213900-26-062458","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2026-05-29T12:42:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vyome Q1 net loss $963K, cash $8.8M, inks JAK inhibitor licensing deal with Impetis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of approx. $963K ($0.15 per share) for Q1 ended March 31, 2026.","Cash and equivalents $8.8M, up from $5.0M at Dec 31, 2025; no debt or toxic financing.","In-licensed two selective JAK inhibitor assets from Impetis Biosciences (TATA Enterprise) for global ~$57B market.","Filed Orphan Drug Designation application for VT-1953 with FDA; submitted proposals for pivotal development guidance.","Raised $5.29M via sale of 1,089,545 shares at $5.00 (59.2% premium to prior close); ~15% dilution."],"consensus_eps_estimate":-0.1836,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":31591.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92801,"accession_number":"0001213900-26-049312","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Vyome stockholders approve reducing authorized common shares from 300M to 50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders voted to decrease authorized common stock from 300M to 50M shares; Certificate of Tenth Amendment filed.","Total authorized shares now 60M (50M common + 10M preferred).","Approximately 65.57% of outstanding shares represented at the 2026 Annual Meeting held April 24.","Elected Venkat Nelabhotla and John Tincoff as Class II directors for three-year terms.","Ratified Kreit & Chiu CPA LLP as independent auditor for FY 2026; advisory 'say-on-pay' passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103936,"accession_number":"0001213900-26-020387","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Livechain acquires Humanyze debt for stock; seeks exchange uplisting","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["LICH acquired $5.765M senior secured convertible note of Humanyze from Remus Capital in exchange for 211.2M shares of LICH common stock (25% diluted stake).","Transaction valued at ~$325,000; LICH will assume all Humanyze assets and operations via default and asset transfer.","Humanyze is an MIT-incubated AI HR analytics company; Livechain aims to use acquisition to seek uplisting to a national exchange.","Vyome remains majority shareholder of Livechain; deal structured as related party transaction approved by Audit Committee and Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103935,"accession_number":"0001213900-26-015795","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vyome reports positive Phase 2 data for VT-1953 in malignant fungating wounds; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VT-1953 achieved significant reduction in malodor at Day 14 (p=0.002 vs baseline; p=0.0015 vs vehicle).","Secondary endpoint met: patient-reported impact of malodor on QoL improved significantly (p=0.0256 vs vehicle).","Exploratory endpoints showed significant pain reduction (p=0.002) and improved composite QoL at Day 14.","No treatment-emergent adverse events or safety signals reported across the 15-patient study.","Company filed for orphan drug designation and plans to discuss Phase 3 design with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103934,"accession_number":"0001213900-26-008575","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vyome VT-1953 valuation: $455M rNPV, potential $1.086B after Phase 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Independent report values VT-1953 at $455M rNPV in H1 2026, growing to $1.086B post-Phase 3 in H1 2028.","No FDA-approved therapies for malignant fungating wounds; 56.5% probability of approval assumed.","Peak net sales imply $2.2B TAM in 2026, $2.8B by 2040; 30% market share modeled.","Pricing $20/gram ($9,125/month); Phase 3 starts Q3 2026, NDA and launch targeted Q4 2028.","Development costs to 2028 estimated at $10M; potential partners include BMS and Pierre Fabre."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120211,"accession_number":"0001213900-25-125310","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vyome subsidiary LiveChain to acquire Remus Note for 25% of LICH stock; related-party deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LICH will issue 25% of its fully diluted common stock to Remus for a Humanyze senior secured convertible note.","Additional 10% of LICH stock reserved for employees; current LICH shareholders expected to own 65% post-closing.","LICH to pay $20,000 good faith deposit to Humanyze; definitive agreements due within 30 days, closing within 45 days thereafter.","Transaction is a related-party deal; Remus founder Krishna Gupta and partners recused from Vyome board and audit committee votes.","Remus gets right to appoint one director to LICH board post-closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120210,"accession_number":"0001213900-25-112728","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vyome reports Q3 cash $5.7M; VT-1953 Phase 2 interim hits primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VT-1953 Phase 2 interim data: statistically significant malodor reduction (p<0.001); pain and QoL improved; safety profile excellent.","Cash, equivalents & short-term investments $5.7 million; expected runway through end of 2026 inclusive of clinical trials.","Net loss primarily from one-time merger/financing non-cash charges; company is pre-revenue clinical stage.","Clean capital structure: 5,556,295 shares outstanding, no preferred stock, no warrants or convertible notes.","Acquired MIT startup Oculo to launch AI strategy; hired new CTO and SVP of Clinical Development with Big Pharma backgrounds."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":283163.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120209,"accession_number":"0001213900-25-104121","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vyome Holdings shareholders elect three Class I directors, approve 2025 equity plan, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["4,258,856 shares (77.52% of eligible) represented; all three Class I directors elected with ~3,955,642 votes for each.","Krishna K. Gupta, Dr. Shiladitya Sengupta, and Stash Pomichter elected to serve until 2028 annual meeting.","2025 Equity Incentive Plan approved: 3,766,413 for, 184,403 against, 301,440 broker non-votes.","Ratification of Kreit & Chiu CPA LLP as auditor: 4,248,216 for, 10,081 against, 559 abstain.","Non-binding advisory vote on executive compensation passed: 3,945,592 for, 11,052 against, 772 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120208,"accession_number":"0001213900-25-096156","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vyome acquires MIT AI startup Oculo Health to launch AI psychiatrist targeting inflammation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired substantially all assets of Oculo, Inc., an MIT-launched AI startup.","New business unit to develop an AI psychiatrist for reducing systemic inflammation.","AI subcommittee formed with MIT alumni Krishna Gupta, Mohanjit Jolly, and Stash Pomichter.","Company remains fully funded through 2026 to progress core biotech assets.","Transaction will not affect Vyome's existing inflammation-focused biotech programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136784,"accession_number":"0001213900-25-087217","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K/A","filed_at":"2025-09-12T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vyome corrected pro forma statements show combined net loss $522k, revenue $249k for H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrected pro forma for H1 2025: combined net loss $522k, revenue $249k, EPS $(0.07).","Vyome shareholders to own 92.4% of combined company on fully-diluted basis post-merger.","Asset sale to Biorad for $1.6M in cash; concurrent financing totals $7.3M, including $660k bridge notes.","Pro forma weighted-average shares of 7,191,409; combined total assets $6.95M, equity $4.79M.","Merger closed August 14, 2025; filing corrects previously erroneous pro forma calculations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136787,"accession_number":"0001213900-25-082924","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vyome Holdings files pre-merger financials: H1 2025 net loss $603K, revenue $249K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $602,732 for six months ended June 30, 2025, vs $593,132 in prior year.","Revenue of $248,536, up from $110,990 year-over-year; cost of goods sold $69,881.","Current liabilities exceed current assets by ~$6M as of June 30, 2025; going concern doubt noted.","Cash and cash equivalents $383K vs $102K at Dec 31, 2024; convertible debt $4.03M.","Board approved 5,000:1 reverse stock split in August 2025 prior to merger close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136786,"accession_number":"0001213900-25-079045","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["1.01","4.01","9.01"],"status":"ready","headline":"Vyome Holdings increases ATM offering from $3.42M to $12M; appoints new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased at-the-market offering capacity from $3.42M to $12M via Amendment to Equity Distribution Agreement with Maxim Group.","Dismissed Haskell & White as auditor; appointed Kreit & Chiu CPA LLP for FY 2025.","Prior auditor's 2024 report included going concern doubt about company's viability.","No disagreements with former auditor; but material weaknesses in internal controls as of Dec 31, 2024 reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136785,"accession_number":"0001213900-25-078603","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.01","3.02","3.03","5.02","5.03","9.01"],"status":"ready","headline":"Vyome Holdings (HIND) completes merger and asset sale, appoints new CEO and board","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed: Vyome Therapeutics becomes subsidiary; company renamed Vyome Holdings, Inc.","Asset sale: ReShape sold its assets to Biorad for $2.25M cash, assuming substantially all liabilities.","Reverse stock split: 1-for-4 split effective Aug 15, 2025 to meet Nasdaq minimum bid price.","Leadership: New CEO Venkateswarlu Nelabhotla, interim CFO Robert Dickey; six new directors appointed.","Equity sale: 529,137 shares sold at $11.02 per share in unregistered offering post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136783,"accession_number":"0001104659-25-076151","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve asset sale to Ninjour Health and merger-related charter amendments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset Sale to Ninjour Health International Ltd approved: 1,273,715 For, 26,206 Against, 2,305 Abstentions.","Charter amendment for Vyome Therapeutics merger approved: 1,240,191 For, 58,555 Against, 3,480 Abstentions.","Special Meeting reconvened on August 7, 2025 after adjournment on July 24, 2025 to vote on these proposals.","Amendments to Article VI of Restated Certificate of Incorporation will take effect at merger close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136782,"accession_number":"0001104659-25-070826","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ReShape Lifesciences shareholders approve reverse split, stock issuance; asset sale vote postponed to Aug 7","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposals 1,4,5,6 approved; meetings on asset sale (Prop 2) and merger charter (Prop 3) adjourned to Aug 7.","Prop 1 (shares for merger) passed: 583,748 for, 59,520 against, 235,196 abstain, 604,121 broker non-votes.","Prop 4 (reverse stock split 1:2 to 1:5) approved: 1,249,487 for, 227,492 against, 5,606 abstain.","Reconvened meeting Aug 7 at 11:30am ET virtual; record date remains June 9, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136781,"accession_number":"0001104659-25-068082","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ReShape furnishes investor presentation for pending Vyome merger, new ticker HIND","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed investor presentation slides on July 15, 2025 in connection with proposed merger with Vyome Therapeutics.","Presentation describes Vyome as a US-India clinical-stage platform focused on immuno-inflammation assets.","Combined company expected to trade on Nasdaq under ticker symbol HIND (pending stockholder and regulatory approvals).","Merger and asset sale subject to stockholder vote; joint proxy statement/prospectus filed June 24, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136780,"accession_number":"0001104659-25-065782","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ReShape loans $200K to Vyome at 8% to fund merger-related expenses","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["ReShape (RSLS) issued a $200,000 promissory note to Vyome Therapeutics, bearing 8.0% interest per annum.","Proceeds used for working capital and legal/accounting expenses related to the pending merger under July 8, 2024 agreement.","Note matures on September 30, 2025; if merger closes before then, principal and interest become ReShape net cash.","If merger fails due to Concurrent Financing Default, note becomes senior secured debt of Vyome.","Termination fee reduced by outstanding principal and interest under this note and a prior April 15, 2025 note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154013,"accession_number":"0001104659-25-060706","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ReShape Lifesciences raises ~$6.3M to boost equity above Nasdaq $2.5M minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Raised $3.64M (593K shares) via ATM June 3-6, and $2.64M (1.05M shares) in direct offering June 9.","Proceeds brought stockholders' equity from $1.2M to above the $2.5M Nasdaq minimum.","Despite cure, delisting risk remains; Nasdaq hearing requested to stay suspension.","Company previously disclosed non-compliance with Nasdaq Listing Rule 5550(b)(1) on May 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154012,"accession_number":"0001104659-25-058888","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ReShape Lifesciences prices $2.6M public offering of 1.05M shares at $2.50 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,054,604 shares closed on June 9, 2025; gross proceeds ~$2.6M.","Proceeds to fund general corporate purposes, including expenses for Vyome merger and asset sale to Ninjour.","Maxim Group LLC acted as sole placement agent; receives 7% cash fee and warrants for 52,730 shares at $2.75.","Shares sold at $2.50 per share; shelf registration filed May 2025 and declared effective May 14, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154011,"accession_number":"0001104659-25-057670","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ReShape Lifesciences prices $2.6M public offering of 1.05M shares at $2.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Public offering of 1,054,604 shares at $2.50 per share; gross proceeds $2,636,510.","Since May 30, company has sold $3,642,564 in shares under the ATM offering.","Combined capital raises reduce remaining ATM capacity to $3,420,926.","Shares offered via previously effective shelf registration statement (S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154010,"accession_number":"0001104659-25-054876","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ReShape Lifesciences enters $9.7M at-the-market equity distribution agreement with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $9.7M of common stock via ATM offering; effective May 30, 2025.","Maxim receives 3.0% commission on gross proceeds plus up to $50K legal fee reimbursement and $3K per due diligence session.","Shares sold under existing effective S-3 shelf registration (File No. 333-287168).","Company has no obligation to sell; offering ends upon sale of $9.7M or termination by either party."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154009,"accession_number":"0001104659-25-054856","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ReShape Lifesciences receives Nasdaq delisting notice; intends to appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq determined to delist RSLS for failing to meet $2.5M stockholders' equity requirement by May 27, 2025 extension deadline.","Trading will be suspended June 6 unless the company appeals by June 4; a Form 25-NSE will then remove securities from listing.","Company intends to appeal to a Nasdaq hearings panel, which would stay suspension pending decision.","No assurance hearings panel will grant continued listing or that compliance with listing rules can be maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154008,"accession_number":"0001104659-25-053285","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vyome Q1 2025 net loss widens to $294K; going concern raises risk for ReShape merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vyome revenue rose to $198.6K (Q1 2025) from $77.0K YoY, but net loss widened from $127K to $294K.","Current liabilities exceed current assets by $5.2M; substantial doubt about Vyome's going concern is disclosed.","Convertible debt current portion stands at $3.84M; company relies on continued note issuances for funding.","Pro forma combined financials filed as part of ReShape's S-3 shelf registration for the pending merger.","Vyome plans FDA meeting for VT-1953 pivotal trial in Q3 2025; has Phase III-ready acne program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154007,"accession_number":"0001104659-25-046717","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"ReShape Lifesciences implements 1-for-25 reverse stock split effective May 9, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio effective at trading open on May 9, 2025; each 25 shares become 1.","Stockholders approved the split at special meeting on April 1, 2025; fractional shares rounded up.","Authorized shares unchanged; proportional adjustments to warrants, options, and convertible preferred.","New CUSIP for post-split common stock is 76090R408."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154006,"accession_number":"0001104659-25-040184","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ReShape Lifesciences amends asset purchase deal; price cut to $2.25M, deadline to June 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exercise price under Asset Purchase Agreement reduced from $5.16M to $2.25M.","Termination date extended from March 31, 2025 to June 30, 2025.","Amendment dated April 25, 2025, between ReShape and Ninjour Health International Limited.","Original Asset Purchase Agreement was entered into on July 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154005,"accession_number":"0001104659-25-036837","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ReShape Lifesciences provides $400k loan to Vyome, extends merger deadline to June 30","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["ReShape loans Vyome up to $400k in three tranches at 8% interest, due Sept 30, 2025.","Merger termination date extended from March 31 to June 30, 2025.","Termination fee reduced to $1M minus outstanding note amounts if ReShape terminates.","Note becomes senior secured if merger fails due to concurrent financing default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154004,"accession_number":"0001104659-25-030900","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve reverse split authorization, warrant exercise, and ELOC issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized reverse stock split at ratio 1:2 to 1:250, board discretion within one year; 2,267,177 for, 26,063 against.","Approved exercisability of 2,703,862 warrants and issuance of up to 15,132,975 shares (no exercise price paid); 106,509 for, 42,803 against.","Approved ELOC purchase agreement to sell up to $5,000,000 shares over 36 months; 1,444,858 for, 439,026 against, 409,685 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172646,"accession_number":"0001104659-25-026123","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gary Blackford resigns from Board effective March 15; Audit Committee short one member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gary Blackford resigned from the Board and all committees effective March 15, 2025; not due to any disagreement with the Company.","Audit Committee now has only two independent directors, violating Nasdaq Listing Rule 5605(c)(2)(A) requiring three.","Company will rely on Nasdaq cure period under Rule 5605(c)(4)(B) to regain compliance with audit committee composition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172645,"accession_number":"0001104659-25-015658","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"ReShape Lifesciences prices $6M public offering of 2.6M units at $2.33/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6M from offering of 2,575,107 units at $2.33/unit; closed Feb 18, 2025.","Each unit consists of one common share (or pre-funded warrant) and one warrant to buy one share at $5.83, subject to stockholder approval.","Warrants have reset mechanism (floor $1.25) and alternative cashless exercise (1.2x shares); expire after merger or 60 days post approval.","Net proceeds for general corporate purposes, merger with Vyome, asset sale to Ninjour; up to 50% to prepay Ascent Partners note.","Maxim Group LLC acted as sole placement agent with 7% cash fee and 128,755 placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172644,"accession_number":"0001104659-25-004884","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ReShape Lifesciences amends convertible note, extends maturity to April 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended to earlier of Vyome Therapeutics merger close or 90 days after Jan 14, 2025 (April 16, 2025).","Mandatory prepayment of subsequent financing proceeds reduced from 66% to 50%.","Investor not required to convert the note at merger closing; $45,000 cash extension fee payable at maturity.","Amendment executed with Ascent Partners Fund LLC on $833,333.34 senior secured convertible note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189655,"accession_number":"0001104659-24-132132","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ReShape Lifesciences enters up to $5M equity purchase agreement with investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity purchase agreement for up to $5M over 36 months; pricing at 93% of prior-day VWAP with a true-up mechanism.","Investor receives 17,300 shares and pre-funded warrant for 21,015 shares as commitment fee; short selling prohibited.","Issuance capped at 19.9% of outstanding shares unless stockholder approval or price exceeds Nasdaq Official Closing Price thresholds.","Proceeds expected for working capital and merger with Vyome Therapeutics; 66% of net proceeds must prepay existing convertible note.","Company filed S-1 to register resale of shares; agreement may be terminated by Company on 5 days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189654,"accession_number":"0001104659-24-127477","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ReShape Lifesciences announces pending merger with Vyome Therapeutics; ticker to change to $HIND","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Merger with Vyome Therapeutics Inc. and asset sale to Biorad Medisys or affiliate.","Ticker symbol to change from RSLS to HIND upon closing.","Investor presentation furnished as Exhibit 99.1, highlighting clinical-stage immunoinflammation assets.","No specific deal value or premium disclosed in this filing.","Approval required from ReShape stockholders; joint proxy statement/prospectus to be filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189653,"accession_number":"0001104659-24-124568","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ReShape Lifesciences receives Nasdaq delisting notice for stockholders' equity below $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["As of Sept 30, 2024, stockholders' equity was $1,487,000, below Nasdaq's $2.5M minimum.","Company has 45 days to submit a compliance plan; if accepted, Nasdaq may grant up to 180-day extension.","Intends to monitor performance and consider available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189652,"accession_number":"0001558370-24-015734","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ReShape reports Q3 rev $2.3M (+6.4% YoY); merger with Vyome, asset sale to Biorad for $5.16M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q3 revenue $2.3M, up 6.4% YoY and 16.6% sequentially; gross margin 62.8%.","Operating expenses down 40.6% in first 9 months of 2024 vs 2023.","Merger with Vyome: ReShape stockholders to own ~11.1% of combined company.","Asset sale to Biorad for $5.16M cash; includes Lap-Band, Obalon, DBSN systems.","Received Health Canada approval for Lap-Band 2.0 FLEX and $241K NIH grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189651,"accession_number":"0001104659-24-109401","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"ReShape Lifesciences issues $833,333 senior secured convertible note to institutional investor","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $833,333.34 convertible note with 10% annual interest, due Jan 16, 2025 or upon close of Vyome merger.","Investor received 7,983 shares of common stock as commitment shares in connection with the note.","Note is secured by substantially all assets of ReShape Lifesciences, including intellectual property and patents.","Directors and officers entered lock-up agreements barring disposal of company shares while note is outstanding.","Investor agreed to a leak-out restriction limiting daily sales to 10% of composite trading volume of RSLS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206144,"accession_number":"0001558370-24-012969","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"ReShape Lifesciences announces 1-for-58 reverse stock split effective Sept 23, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split ratio 1:58, effective at trading open on September 23, 2024.","Fractional shares resulting from the split will be rounded up to the nearest whole share.","Proportional adjustments made to outstanding warrants, stock options, and convertible preferred.","Authorized shares unchanged; split approved by stockholders on February 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206143,"accession_number":"0001558370-24-012263","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ReShape Lifesciences enters merger with Vyome Therapeutics, sells assets to Biorad for $5.16M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q2 revenue $2.0M (-12.8% YoY); six-month revenue $3.9M (-13.9% YoY); gross margin improved to 57.7%.","Operating expenses down 45.4% in first half; sales & marketing fell 69.2% in Q2 to $0.7M.","Cash and restricted cash $1.2M as of June 30, with net working capital $2.9M.","Merger with Vyome: all-stock deal; ReShape stockholders to own ~11.1% of combined company.","Asset sale to Biorad Medisys for $5.16M cash; assets include Lap-Band and Obalon systems."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206142,"accession_number":"0001558370-24-009704","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"ReShape Lifesciences announces reverse merger with Vyome Therapeutics and asset sale for $5.16M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Vyome stockholders will own 88.9% of combined company; ReShape stockholders to own 11.1%.","ReShape sells substantially all assets to Ninjour (Biorad Medisys affiliate) for $5.16M cash; Merger closes immediately after.","Series C Preferred liquidation preference reduced from $26.2M to at most $1M or 20% of asset sale price or excess net cash.","Up to $7.3M in concurrent financing includes $5.8M common stock at 30% discount to post-merger valuation.","CEO Paul Hickey receives severance increase to 18 months base salary and 4% fully diluted shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223192,"accession_number":"0001558370-24-008491","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ReShape Lifesciences Q1 rev $1.9M (-15% YoY), gross margin up to 59.9%, opex down 51%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.9M, down 15% YoY; gross margin improved to 59.9% (from 53.5%) due to lower overhead.","Total operating expenses down 51% YoY; sales & marketing down 53%, G&A down 56%.","Cost reduction plan expected to cut 2024 opex by ~55% vs 2023; RIF implemented.","Cash and equivalents $2.5M; net working capital $4.4M.","Lap-Band 2.0 FLEX launch underway; intragastric balloon patent issued; M&A search with Maxim Group."],"consensus_eps_estimate":-946.56,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1944000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223191,"accession_number":"0001558370-24-004933","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"ReShape Lifesciences gets Nasdaq bid-price extension until Oct 7, 2024; may reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff notice on April 9, 2024, that minimum $1.00 bid price still not met.","Granted additional 180-day compliance period; deadline now October 7, 2024.","If closing bid price ≥ $1.00 for 10 consecutive business days, compliance confirmed.","Failure by Oct 6, 2024 triggers delisting notice; company may appeal to Hearings Panel.","Stockholders approved reverse stock split ratio between 1:10 and 1:60 to remedy deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223190,"accession_number":"0001558370-24-004898","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ReShape Lifesciences dismisses RSM, appoints Haskell & White as auditor; prior reports cited going concern doubt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective April 8, 2024, RSM US LLP dismissed as independent auditor; Haskell & White LLP engaged for FY2024 and interim periods.","RSM's audit reports for FY2023 and FY2022 contained an emphasis-of-matter paragraph regarding substantial doubt about the company's ability to continue as a going concern.","No disagreements with RSM on accounting principles, financial disclosure, or audit scope during FY2023, FY2022, or through the dismissal date.","Previously reported material weaknesses in internal control over financial reporting for FY2023 and FY2022 remain on file."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223189,"accession_number":"0001558370-24-004700","cik":1427570,"company_name":"Vyome Holdings, Inc","ticker":"HIND","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ReShape Lifesciences reports FY2023 revenue of $8.7M, down 22.8% as GLP-1 drugs pressure bariatric market","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $8.7M, down 22.8% YoY; Lap-Band unit sales fell 26.8% due to GLP-1 competition.","Gross profit $5.5M (63.9% margin vs 60.5% in 2022); sales & marketing expenses cut 46.8% to $7.5M.","Cash $4.5M and debt-free; expects 2024 operating expenses to decrease >50% vs 2023 via further RIF.","Received FDA approval for Lap-Band 2.0 FLEX in Dec 2023; first surgeries completed in Feb 2024."],"consensus_eps_estimate":-946.56,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1944000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":16282985.25,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}